All In Biotech

Drug Trial Radar · NCT07235462

A Study to Learn About the Use of Acoramidis in Patients With a Heart Condition Called Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in a Real-world Setting

ACO-REAL - A Non-interventional Study Providing Insights Into the Use of Acoramidis in Patients With ATTR Amyloidosis With Cardiomyopathy (ATTR-CM) in Routine Clinical Practice

Last checked: Nov 20, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

2,000

Planned (sponsor's estimate)

Start

Oct 29, 2025

Primary completion

Apr 30, 2028

Study completion Apr 30, 2028

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Nov 19, 2025

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) is a serious and life-threatening condition where a protein called transthyretin (TTR) misfolds and builds up as amyloid fibrils in the heart muscle. This buildup causes the heart to become stiff, leading to restrictive cardiomyopathy and progressive heart failure. There are two forms of ATTR-CM: a hereditary or 'variant' form (vATTR-CM) caused by a gene mutation, and a 'wild-type' form (wtATTR-CM) which is associated with aging. Because its symptoms can be similar to other heart conditions, ATTR-CM is often diagnosed late. However, recent advances in medical imaging are helping doctors to identify the disease earlier. Acoramidis is a new medication designed to treat ATTR-CM. It works by stabilizing the TTR protein, preventing it from misfolding and forming the harmful amyloid deposits. Acoramidis has been shown to be effective and safe in a major clinical trial (the ATTRibute-CM study), which led to its approval for use in both the United States and Europe. While clinical trials provide valuable information, data on how a new medicine performs in everyday clinical practice is also very important. This type of information is called real-world evidence. Currently, there is limited real-world information about the use of acoramidis. This study, called ACO-REAL, is an observational study, which means researchers will observe patients who are receiving acoramidis as part of their normal clinical care, without introducing any experimental interventions. The study will take place in approximately 20 European countries and aims to enroll up to 2,000 adults who have been diagnosed with either wild-type or variant ATTR-CM and are starting treatment with acoramidis. This includes patients who have not been treated for ATTR-CM before, as well as those who have been treated with other therapies. The main goals of the study are to understand the characteristics of patients being treated with acoramidis and to document how the treatment is used in routine medical practice. The study will also collect information on the safety of acoramidis. Furthermore, researchers will assess how the treatment affects patients' heart function, their functional capacity (such as their ability to walk), their overall health status, and their quality of life. The study will also track how often patients need to use healthcare resources like hospitals or emergency rooms. This information will help to improve the understanding and management of ATTR-CM in a real-world setting, ultimately aiming to optimize care for patients with this progressive disease.

Conditions

  • Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Interventions

  • Acoramidis (356 mg film-coated tablets)Drug

    Follow clinical practice/administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Patient demographic characteristics: ageTime frame: Baseline (Initial study visit)
  2. Patient demographic characteristics: sexTime frame: Baseline (Initial study visit)
  3. Patient demographic characteristics: raceTime frame: Baseline (Initial study visit)
  4. Patient demographic characteristics: heightTime frame: Baseline (Initial study visit)
  5. Patient demographic characteristics: weightTime frame: Baseline (Initial study visit)
  6. Clinical Characteristics: Transthyretin Amyloid Cardiomyopathy (ATTR-CM) TypeTime frame: Baseline up to 15 months
  7. Clinical Characteristics: Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Genetic statusTime frame: Baseline up to 15 months
  8. Clinical Characteristics: Transthyretin Amyloid Cardiomyopathy (ATTR-CM) DiagnosisTime frame: Baseline up to 15 months
  9. Clinical Characteristics: Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Setting of DiagnosisTime frame: Baseline up to 15 months
  10. Clinical Characteristics: Transthyretin Amyloid Cardiomyopathy (ATTR-CM) ManifestationsTime frame: Baseline up to 15 months
  11. Clinical Characteristics: Transthyretin Amyloid Cardiomyopathy (ATTR-CM) -relevant comorbiditiesTime frame: Baseline up to 15 months
  12. Clinical Characteristics: Transthyretin Amyloid Cardiomyopathy (ATTR-CM) -relevant proceduresTime frame: Baseline up to 15 months
  13. Treatment Patterns with Acoramidis: Transthyretin Amyloid Cardiomyopathy (ATTR-CM) -related medicationsTime frame: Baseline (assessment within the past 12 months prior to initiation)
  14. Treatment Patterns with Acoramidis: Transthyretin Amyloid Cardiomyopathy (ATTR-CM) concomitant medicationsTime frame: Baseline up to 15 months
  15. Treatment Patterns with Acoramidis: InitiationTime frame: Baseline up to 15 months
  16. Treatment Patterns with Acoramidis: Initiation after a different therapyTime frame: Baseline up to 15 months
  17. Treatment Patterns with Acoramidis: discontinuationTime frame: Baseline up to 15 months
  18. Treatment Patterns with Acoramidis: interruptionTime frame: Baseline up to 15 months
  19. Treatment Patterns with Acoramidis: prescription / refillsTime frame: Baseline up to 15 months

Locations

17 sites in 17 countries. Site status is shown where the registry gives one.

  • Many Locations

    Multiple Locations, Austria · Recruiting

  • Many Locations

    Multiple Locations, Belgium · Recruiting

  • Many Locations

    Multiple Locations, Croatia · Recruiting

  • Many Locations

    Multiple Locations, Denmark · Recruiting

  • Many Locations

    Multiple Locations, Estonia · Recruiting

  • Many Locations

    Multiple Locations, Finland · Recruiting

  • Many Locations

    Multiple Locations, Germany · Recruiting

  • Many Locations

    Multiple Locations, Italy · Recruiting

  • Many Locations

    Multiple Locations, Latvia · Recruiting

  • Many Locations

    Multiple Locations, Lithuania · Recruiting

  • Many Locations

    Multiple Locations, Norway · Recruiting

  • Many Locations

    Multiple Locations, Portugal · Recruiting

  • Many Locations

    Multiple Locations, Slovenia · Recruiting

  • Many Locations

    Multiple Locations, Spain · Recruiting

  • Many Locations

    Multiple Locations, Sweden · Recruiting

  • Many Locations

    Multiple Locations, Switzerland · Recruiting

  • Many Locations

    Multiple Locations, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.